Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Abbott Laboratories (ABT) stocks

Abbott Laboratories stock has moved 2.85% from yesterday's closing price. Learn how to easily invest in Abbott Laboratories stock.

Abbott Laboratories is a medical devices business based in the US. Abbott Laboratories stocks (ABT.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $96.76 – a decrease of 3.08% over the previous week. Abbott Laboratories employs 113,000 staff and has a trailing 12-month revenue of around $45.5 billion.

How to buy stocks in Abbott Laboratories

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Abbott Laboratories stock price (NYSE:ABT)

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories shares at a glance

Information last updated 2022-09-26.
Latest market close$96.76
52-week range$98.81 - $140.91
50-day moving average $107.07
200-day moving average $116.93
Wall St. target price$124.94
PE ratio 21.0188
Dividend yield $1.86 (1.87%)
Earnings per share (TTM) $4.79

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
min $1.00, max 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.
loading

Compare up to 4 providers

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Abbott Laboratories price performance over time

Historical closes compared with the close of $96.76 from 2022-09-30

1 week (2022-09-27) -1.60%
1 month (2022-09-02) -5.60%
3 months (2022-07-01) -12.21%
6 months (2022-03-31) -18.25%
1 year (2021-10-01) -17.45%
2 years (2020-10-02) -9.15%
3 years (2019-10-04) 18.01%
5 years (2017-10-03) 80.02%

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Abbott Laboratories shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 15.9572. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14 billion.

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

Abbott Laboratories financials

Revenue TTM $45.5 billion
Operating margin TTM 23.22%
Gross profit TTM $25 billion
Return on assets TTM 8.96%
Return on equity TTM 24.18%
Profit margin 18.78%
Book value $20.84
Market capitalisation $176.3 billion

TTM: trailing 12 months

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 01/01/2019) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Abbott Laboratories share dividends

32%

Dividend payout ratio: 31.97% of net profits

Recently Abbott Laboratories has paid out, on average, around 31.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.87% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $1.86 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 15 November 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 October 2022 (the "ex-dividend date").

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 2 January 2013. So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as $98.81 up to $140.9084. A popular way to gauge a stock's volatility is its "beta".

ABT.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.7123. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

Abbott Laboratories overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site